EP Patent

EP4014965A1 — Aqueous solution

Assigned to Ever Valinject GmbH · Expires 2022-06-22 · 4y expired

What this patent protects

The present invention relates to an aqueous solution comprising glycopeptide antibiotics, selected from the group consisting of vancomycin, telavancin, oritavancin, teicoplanin, dalbavancin and mixtures thereof, especially vancomycin, and a mixture of D- and L- enantiomers of N-p…

USPTO Abstract

The present invention relates to an aqueous solution comprising glycopeptide antibiotics, selected from the group consisting of vancomycin, telavancin, oritavancin, teicoplanin, dalbavancin and mixtures thereof, especially vancomycin, and a mixture of D- and L- enantiomers of N-propionylated alanine (pAla), especially a racemic mixture, the solution having a pH of from about 4.0 to 7.0 and being present in a suitable container. The invention relates further to the use of such an aqueous solution as a medicament, especially for use in the treatment of bacterial infections, and a method for stabilizing glycopeptide antibiotics, especially vancomycin.

Drugs covered by this patent

Patent Metadata

Patent number
EP4014965A1
Jurisdiction
EP
Classification
—
Expires
2022-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Ever Valinject GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.